Please note the webcast will not begin until 8:30 AM CT.

Join Senseonics for an in-person and virtual analyst event with company management to discuss the next-generation Eversense^® 365 Continuous Glucose Monitoring (CGM) system, approved by the U.S. Food and Drug Administration (FDA) for people with diabetes aged 18 years and older.

The event will focus on the commercial launch of Eversense 365 and its use in clinical practice. Company management will also discuss plans to advance its pipeline of implantable CGM technology. The event will be held in conjunction with the American Diabetes Association 85th Scientific Sessions (ADA 2025), taking place June 20-23, 2025 in Chicago, Illinois.

A live question and answer session will follow the formal presentations.